Part-Time

Senior Scientist

Statistical Programming

Deadline 9/15/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

No salary listed

North Wales, PA, USA

Hybrid

Part-time telecommuting permitted; up to 10% domestic travel required.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
SAS
Data Structures & Algorithms
SAP Products

Get referred to Merck

See people who can refer or advise you

Requirements
  • Bachelor’s degree or equivalent in Computer Science, Statistics, Applied Mathematics, Life Sciences, Engineering or related field and 5 years of experience in the position offered or a related SAS programming role within a clinical trial environment; or a Master’s degree in these fields and 3 years of experience in the position offered or a related SAS programming role within a clinical trial environment.
  • Must have 3 years of experience with all the following:
  • SAS and clinical trial programming, including data steps, procedures, SAS/MACRO, and SAS/GRAPH; systems and database.
  • Designing and developing complex programming algorithms.
  • Comprehending analysis plans describing methodology to be programmed.
  • Understanding statistical terminology and concepts; clinical data management concepts; CDISC and ADaM standards.
  • Ensuring process compliance and deliverable quality.
  • Designing statistical databases that optimize analysis and reporting.
Responsibilities
  • Apply state-of-the art scientific methodologies and tools to enable the discovery, development, regulatory approval, manufacturing, and marketing of medical drugs and vaccines for the benefit of patients and global human health.
  • Support statistical programming activities for late-stage drug/vaccine clinical development projects, including leadership of one or more projects.
  • Responsible for the development and execution of statistical analysis and reporting deliverables (e.g. safety and efficacy analysis datasets, tables, listings, figures), the span of which range from individual clinical trials to world-wide regulatory application submissions and post marketing support.
  • Responsible for the design and maintenance of statistical datasets that support multiple stakeholder groups which include clinical development, outcomes research and safety evaluation.
  • Act as a key collaborator with statistics and other project stakeholders in ensuring that project plans are executed efficiently with timely and high-quality deliverables.
  • Provide SAS programming support for Clinical Trials from Phase I through Phase III.
  • Utilize the CDISC Analysis Data Model (ADaM) dataset specifications and SDTM data to programmatically develop analysis datasets by writing several lines of code in statistical software (e.g. SAS).
  • Write code for Tables, Listings and Figures (TLFs) macros and implement statistical methodologies.
  • Generate TLFs as per the SAP by executing analysis dataset programs and TLF macros.
  • Serve as the Statistical Programming point of contact and knowledge holder through the entire product lifecycle on assigned projects.
  • Maintain and manage a project plan including resource forecasting.
  • Coordinate the activities of a global programming team that includes outsource provider staff.
  • Support NDA/BLA submissions and addressing agency questions as required.
  • Mentor junior programmers and work with third party vendor programs.
  • Part-time telecommuting permitted.
  • Up to 10% domestic travel required.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck raised 2026 revenue guidance to $66.3 billion-$67.3 billion after Q2 beat.
  • KEYTRUDA QLEX generated $463 million in Q2 2026, proving physician adoption.
  • INTerpath-001 opens melanoma and nine additional trials across lung, bladder, kidney, pancreas.

What critics are saying

  • Keytruda patents start expiring in 2028, threatening over half of quarterly revenue.
  • Merck cut about 150 Gardasil jobs in February 2026 as vaccine demand weakened.
  • If intismeran falters outside melanoma, Merck faces a post-Keytruda growth vacuum.

What makes Merck unique

  • Keytruda remains Merck’s oncology engine, with $8.37 billion Q2 2026 sales.
  • Merck and Moderna’s INTerpath-001 delivered the first positive Phase 3 personalized cancer-vaccine readout.
  • Subcutaneous Keytruda QLEX and new TNBC approval extend Merck’s regimen-and-delivery moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.